Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momordica Charantia for Glycemic Control in Type 2 Diabetes
NCT00823953Phase 2Withdrawn
- Sponsor
- Services Hospital Lahore
- Start
- Nov 2008
- Primary completion
- Feb 2009
- Modality
- Botanical Extract
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Momordica charantia with Placebo (2 arms). Primary endpoint: serum fructosamine at 3 weeks. Planned start Nov 2008; status: withdrawn.
02
Drugs
momordica charantia extract
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00823953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00823953.